Skip to content
AnalystLens

BridgeBio Pharma Annual Report, Year Ended Dec 31, 2019

Filing Date
Filed March 3, 2020
Period End
December 31, 2019
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Oct ’21Oct ’21
  2. Material agreement8-K · Sep ’23Sep ’23
  3. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 10-K filed March 3, 2020. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (BBIO) is a clinical-stage biopharmaceutical company, founded in 2015, that is developing medicines for Mendelian diseases and genetically driven cancers through a decentralized structure in which each program sits in its own subsidiary.

As of December 31, 2019, the company reported over 20 development programs, with four key value drivers: BBP-265 (AG10, Eidos) for ATTR, infigratinib (BBP-831) for FGFR-driven cancers and achondroplasia, BBP-631 for CAH, and BBP-454 for KRAS-driven cancers. The company has not generated product revenue; its only 2019 revenue was license revenue of $40.6 milliona, mainly from the Alexion license agreement for BBP-265 in Japan. The company incurred a net loss of $288.6 million in 2019, compared with $169.5 million in 2018 and $43.8 million in 2017, and had an accumulated deficit of $440.0 million.

Research and development expense rose to $209.9 millionb from $140.1 million, and general and administrative expense rose to $94.4 million from $43.6 million. At year-end, cash, cash equivalents and marketable securities totaled $577.1 million, or $385.9 million excluding Eidos, and debt was $91.8 million net. The company stated that it expects its cash to fund operations for at least the next 12 months.

Its July 2019 IPO on Nasdaq under the symbol BBIO raised net proceeds of approximately $366.2 millionc. Key near-term catalysts include the ongoing Phase 3 ATTRibute-CM trial of BBP-265 (12-month 6MWD data expected in 2021), planned NDA submission for infigratinib in second-line CCA in 2020, a Phase 3 first-line CCA trial, and an ATTR-PN Phase 3 start in the first half of 2020. The filing also discloses that the company identified material weaknesses in internal control in its 2017 audit and states that these were remediated as of December 31, 2019.

Key Highlights

  1. No product revenue to date; 2019 license revenue was $40.6 million, primarily from the Alexion license of BBP-265 in Japan (with a $25.0 million upfront payment).
  2. Net loss widened to $288.6 million in 2019 from $169.5 million in 2018; accumulated deficit reached $440.0 million.
  3. R&D expense increased to $209.9 million (from $140.1 million) and G&A rose to $94.4 million (from $43.6 million), driven by external program costs and public-company preparation.
  4. Cash, cash equivalents and marketable securities were $577.1 million at year-end ($385.9 million excluding Eidos), with management expecting funding for at least the next 12 months.
  5. IPO completed July 1, 2019 at $17.00 per share, with net proceeds of approximately $366.2 million.
  6. Lead asset BBP-265 is in a Phase 3 ATTRibute-CM trial; 12-month 6MWD data is expected in 2021. A Phase 2 study showed mean serum TTR increases of 36% (400 mg) and 50% (800 mg) versus baseline.
  7. Infigratinib (BBP-831) Phase 2 CCA interim data showed an ORR of 26.9% in FGFR2 fusion-positive patients; an NDA for second-line CCA is planned for 2020.

Financial Statements

FY2019 against FY2018

Line itemFY2019FY2018Change
Revenue$40.56M——
R&D Expenses$209.95M$140.07M+49.9%
SG&A Expenses$94.35M——
Operating Expenses$306.80M$183.66M+67.0%
Operating Income-$266.24M-$183.66M−45.0%
Interest Expense$8.77M$2.55M+244.1%
Net Income-$260.59M-$130.75M−99.3%
EPS (Basic)$-2.48$-2.12−17.0%
Shares Outstanding (Basic)105.10M61.77M+70.2%

Frequently Asked Questions

  1. Does BridgeBio have any approved products or revenue from product sales?

    No. The company states it has no products approved for commercial sale and has not generated revenue from product sales. Its 2019 license revenue of $40.6 million came from licensing arrangements, mainly the Alexion agreement for BBP-265 in Japan and a QED license with a Perceptive-affiliated licensee.

  2. How much cash does the company have, and is it enough to fund operations?

    As of December 31, 2019, cash, cash equivalents and marketable securities totaled $577.1 million, or $385.9 million excluding Eidos. The company expects these funds to support operations for at least the next 12 months, but it notes it may need additional funding sooner if plans change.

  3. What are the main near-term clinical and regulatory milestones?

    The company plans to submit an NDA for infigratinib in second-line advanced CCA with FGFR2 fusions in 2020, begin a Phase 3 ATTR-PN trial of BBP-265 in the first half of 2020, and report 12-month 6MWD data from the ATTRibute-CM Phase 3 trial in 2021. It also expects to complete the BBP-589 Phase 1/2 trial in 2020.

  4. What are the main risks highlighted in the filing?

    The filing highlights the company's history of losses and need for substantial additional capital, dependence on clinical trial outcomes and regulatory approval, reliance on third-party CMOs and CROs (some single-source), intellectual property and licensing dependencies, competition from larger companies (including Pfizer's tafamidis for ATTR-CM), and dependence on key personnel and on its subsidiary structure.